Cardiovascular risk in rheumatoid arthritis: Comparing tnf-α blockade with nonbiologic DMARDs

American Journal of Medicine

Volumn 126, Issue 8, 2013, Pages 730.e9-730.e17

  Solomon, Daniel H ^a   Curtis, Jeffrey R ^b   Saag, Kenneth G ^b   Lii, Joyce ^a   Chen, Lang ^b   Harrold, Leslie R ^c   Herrinton, Lisa J ^d   Graham, David J ^e   Kowal, Mary K ^a   Kuriya, Bindee ^f   Liu, Liyan ^d   Griffin, Marie R ^g   Lewis, James D ^h   Rassen, Jeremy A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d KAISER PERMANENTE   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g VANDERBILT UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular disease; Rheumatoid arthritis; TNF blocking agents

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; EVENT FREE SURVIVAL; EXPOSURE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 84880612195     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.02.016     Document Type: Article

References (42)

1. M. Cesari, B.W. Penninx, and A.B. Newman Inflammatory markers and onset of cardiovascular events: results from the Health ABC study Circulation 108 19 2003 2317 2322
2. P.M. Ridker, N. Rifai, M. Pfeffer, F. Sacks, S. Lepage, and E. Braunwald Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction Circulation 101 18 2000 2149 2153
3. D.M. Lee, and M.E. Weinblatt Rheumatoid arthritis Lancet 358 9285 2001 903 911
4. M. Feldmann, F.M. Brennan, and R.N. Maini Role of cytokines in rheumatoid arthritis Annu Rev Immunol 14 1996 397 440
5. D.H. Solomon, E.W. Karlson, and E.B. Rimm Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 9 2003 1303 1307
6. J.A. Avina-Zubieta, H.K. Choi, M. Sadatsafavi, M. Etminan, J.M. Esdaile, and D. Lacaille Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies Arthritis Rheum 59 12 2008 1690 1697
7. I. del Rincon, G.L. Freeman, R.W. Haas, D.H. O'Leary, and A. Escalante Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis Arthritis Rheum 52 11 2005 3413 3423
8. D.H. Solomon, J. Kremer, and J.R. Curtis Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity Ann Rheum Dis 69 11 2010 1920 1925
9. G.D. Kitas, and S.E. Gabriel Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives Ann Rheum Dis 70 1 2011 8 14
10. A. Naranjo, T. Sokka, and M.A. Descalzo Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study Arthritis Res Ther 10 2 2008 R30
11. L.T. Jacobsson, C. Turesson, and A. Gulfe Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis J Rheumatol 32 7 2005 1213 1218
12. L. Carmona, M.A. Descalzo, and E. Perez-Pampin All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists Ann Rheum Dis 66 7 2007 880 885
13. J.D. Greenberg, J.M. Kremer, and J.R. Curtis Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis Ann Rheum Dis 70 4 2011 576 582
14. M.H. Weisman, H.E. Paulus, and F.X. Burch A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases Rheumatology (Oxford, England) 46 7 2007 1122 1125
15. W.G. Dixon, K.D. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, and D.P. Symmons Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 56 9 2007 2905 2912
16. D.H. Solomon, J. Avorn, and J.N. Katz Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis Arthritis Rheum 54 12 2006 3790 3798
17. S. Suissa, S. Bernatsky, and M. Hudson Antirheumatic drug use and the risk of acute myocardial infarction Arthritis Rheum 55 4 2006 531 536
18. L.J. Herrinton, J.R. Curtis, and L. Chen Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems Pharmacoepidemiol Drug Saf 20 11 2011 1199 1209
19. J.A. Rassen, D.H. Solomon, J.R. Curtis, L. Herrinton, and S. Schneeweiss Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics Med Care 48 6 Suppl 2010 S83 S89
20. S.Y. Kim, A. Servi, and J.M. Polinski Validation of rheumatoid arthritis diagnoses in health care utilization data Arthritis Res Ther 13 1 2011 R32
21. Y. Kiyota, S. Schneeweiss, R.J. Glynn, C.C. Cannuscio, J. Avorn, and D.H. Solomon Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records Am Heart J 148 1 2004 99 104
22. E. Birman-Deych, A.D. Waterman, Y. Yan, D.S. Nilasena, M.J. Radford, and B.F. Gage Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors Med Care 43 5 2005 480 485
23. N.N. Choma, M.R. Griffin, and R.L. Huang An algorithm to identify incident myocardial infarction using Medicaid data Pharmacoepidemiol Drug Saf 18 11 2009 1064 1071
24. C.S. Fox, J.C. Evans, and M.G. Larson A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death Am J Cardiol 95 7 2005 856 859
25. C.P. Chung, K.T. Murray, C.M. Stein, K. Hall, and W.A. Ray A computer case definition for sudden cardiac death Pharmacoepidemiol Drug Saf 19 6 2009 563 572
26. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
27. M.L. Johnson, W. Crown, B.C. Martin, C.R. Dormuth, and U. Siebert Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - Part III Value Health 12 8 2009 1062 1073
28. D.Y. Lin, L.J. Wei, and Z. Ying Checking the Cox model with cumulative sums of Martingale-based residuals Biometrika 80 1993 557 572
29. K.J. Rothman No adjustments are needed for multiple comparisons Epidemiology 1 1 1990 43 46
30. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
31. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 14 1997 973 979
32. S. Schneeweiss Developments in post-marketing comparative effectiveness research Clin Pharmacol Ther 82 2 2007 143 156
33. P.C. Austin Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score Am J Epidemiol 172 9 2010 1092 1097
34. P.C. Austin Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations Biom J 51 1 2009 171 184
35. Pharmacoepidemiology Toolbox version 2. 2011. Available at: http://www.hdpharmacoepi.org. Accessed August 1, 2011.
36. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 9 2003 915 920
37. P. Kleinbongard, G. Heusch, and R. Schulz TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure Pharmacol Ther 127 3 2010 295 314
38. K.M. Kurrelmeyer, L.H. Michael, and G. Baumgarten Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction Proc Natl Acad Sci U S A 97 10 2000 5456 5461
39. D. Hurlimann, A. Forster, and G. Noll Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis Circulation 106 17 2002 2184 2187
40. N.B. Rayment, E. Moss, and L. Faulkner Synthesis of TNF alpha and TGF beta mRNA in the different micro-environments within atheromatous plaques Cardiovasc Res 32 6 1996 1123 1130
41. P. Libby, P.M. Ridker, and A. Maseri Inflammation and atherosclerosis Circulation 105 9 2002 1135 1143
42. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 4 2011 597 605